Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04449380

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients — INTERCOP  

COVID-19 Virus Infection Clinical Trial

Official title:
Randomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-β-1a (IFNβ-1a) in COVID-19 Patients

Clinical Trial Summary

Pharmacological therapies of proven efficacy in coronavirus disease 2019 (COVID-19) are still lacking. Since two clinical stages of COVID-19 are emerging, an early one with typical clinical characteristics of a viral infection (fever, malaise, cough) and a later one with pneumonia leading to progressive respiratory failure, associated with heavy, cytokine-mediated, inflammation, an intervention by a compound possessing both antiviral activity and immunomodulatory effects would be most effective at the earliest possible stage. The purpose of this clinical trial is to test the efficacy of Interferon-β-1a (IFNβ-1a), in COVID-19 patients in an open label, randomized clinical trial. The design of the study is to test IFNβ-1a in addition to standard of care compared with standard of care alone. The primary outcome is the time to negative conversion of Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2) nasopharyngeal swabs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04449380
Study type Interventional
Source IRCCS San Raffaele
Contact
Status Terminated
Phase Phase 2
Start date November 2, 2020
Completion date March 30, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04560881 - Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) Phase 3
Active, not recruiting NCT05208983 - SafeTy and Efficacy of Preventative CoVID Vaccines
Completed NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed NCT05268679 - Covid-19 Vaccine Response in Heart Transplant Recipients
Completed NCT05446961 - Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus Phase 2
Terminated NCT04847583 - A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients Phase 2
Terminated NCT04778059 - Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 Phase 2
Terminated NCT04786808 - Risk Factors for COVID-19 Mortality
Completed NCT05514691 - Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC N/A
Withdrawn NCT05085574 - Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Phase 2
Completed NCT05489367 - Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?
Withdrawn NCT05133635 - High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19 Phase 4
Active, not recruiting NCT05077332 - LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Phase 2
Terminated NCT05077969 - Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) Phase 2
Completed NCT05371561 - Effect of PPE on Children's Fear in Dental Office N/A